Compare McKesson Corporation (MCK) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Nvidia Corp — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while Nvidia Corp trades at $229.45 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 51.4× McKesson Corporation's market cap, and Nvidia Corp pays the higher dividend (0.43%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Nvidia Corp for 115 Days on average.
| MCK | NVDA | |
|---|---|---|
Market Cap | $108.46B | $5.57T |
Volume | 712,607 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $995.69 | $239.27 |
52-Week Low | $725.17 | $165.17 |
Typical Hold Time | 74 Days | 115 Days |
Enterprise Value | $115.00B | $5.54T |
Dividend Yield | 0.4% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
NVIDIA (NVDA) trades at $229.28, down 3.4% today, but maintains strong fundamentals with revenue surging to $130.5B in 2025 and net income reaching $72.88B. The stock shows a bullish technical signal with support at $228 and resistance at $235. Recent earnings beats and a 75.95% analyst buy rating highlight continued growth momentum despite the day's decline.
Outlook remains positive with a consensus price target of $339.17, offering 48% upside. Key risks include increased competition in AI chips and market volatility, but NVIDIA's dominant market position and accelerating AI demand support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
